Class 4 caution in use-Risperidone 1mg, 2mg & 3mg tablets

Sandoz Ltd. has informed the MHRA that there is missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for Risperidone 1mg, 2mg and 3mg and Tablets.

MHRA Drug alert date: 26th September 2024

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-sandoz-ltd-dot-risperidone-1mg-2mg-3mg-tablets-el-24-a-slash-43?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=b4d60715-056e-4313-977a-7a57a225af0e&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information queries, please contact: sandozgb@EU.propharmagroup.com, Telephone: +44 1276 698 101.

For stock control queries, please contact: sales.sandoz-gb@sandoz.com, Telephone: +44 1276 698607.